ACRO Biomedical Co (6748.TWO) Stock Price

ACRO Biomedical Co Price

CLOSED
173.00
​
Market closed

Over the last 7 years ACRO Biomedical Co grew revenue by 12.1% annually, reaching 38.26 M TWD. For ACRO Biomedical Co, the net margin of -216.1% is up versus -232.6% a few years ago.

ACRO Biomedical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co business model & stock analysis

ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets.

Frequently asked questions about ACRO Biomedical Co

Converted at the current exchange rate, the ACRO Biomedical Co share trades at 4.70 EUR (173.00 TWD).

The revenue cannot currently be calculated for ACRO Biomedical Co.

The profit cannot currently be calculated for ACRO Biomedical Co.

The P/E ratio cannot be calculated for ACRO Biomedical Co at the moment.

The P/S cannot be calculated for ACRO Biomedical Co currently.

The Eulerpool Quality Score for ACRO Biomedical Co is 5/10.

The ISIN of ACRO Biomedical Co is TW0006748007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ACRO Biomedical Co is 6748.TWO. The ticker symbol is used to trade ACRO Biomedical Co shares on the stock exchange.

Fair ValueTerminal
167.81 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Jul 27, 2021
ISIN
TW0006748007
Cusip
Y000YY101
Market capitalization
12.32 B TWDLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
11.16
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.48 %
Last updated Nov 11, 2026, 5:02 PM

ACRO Biomedical Co Peer Group

ACRO Biomedical Co FIGI

6748:TT (Taipei Stock Exchange) · BBG011W9RRN7